Platelet reactivity testing

An objective analysis of current capability

Julie H. Oestreich, Paul P Dobesh

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

High on-treatment platelet reactivity is associated with adverse cardiovascular events following percutaneous coronary intervention. In analyses based on areas under receiver operating characteristic curves, platelet reactivity tests have poor-to-fair ability to discriminate between patients who are at risk of ischemic events and those who are not. The optimal platelet reactivity test has yet to be determined, and no large, randomized trial to date has successfully demonstrated the effectiveness of tailoring antiplatelet medications according to the platelet reactivity of individual patients for improved clinical outcomes. Therefore, the present role for platelet reactivity monitoring is selective and limited. Copyright Remedica Medical Education and Publishing.

Original languageEnglish (US)
Pages (from-to)55-62
Number of pages8
JournalAcute Coronary Syndromes
Volume10
Issue number2
StatePublished - Sep 6 2011

Fingerprint

Blood Platelets
Percutaneous Coronary Intervention
ROC Curve
Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Platelet reactivity testing : An objective analysis of current capability. / Oestreich, Julie H.; Dobesh, Paul P.

In: Acute Coronary Syndromes, Vol. 10, No. 2, 06.09.2011, p. 55-62.

Research output: Contribution to journalReview article

@article{5f39fcc4f5474aa59f164fcb99bc7e5b,
title = "Platelet reactivity testing: An objective analysis of current capability",
abstract = "High on-treatment platelet reactivity is associated with adverse cardiovascular events following percutaneous coronary intervention. In analyses based on areas under receiver operating characteristic curves, platelet reactivity tests have poor-to-fair ability to discriminate between patients who are at risk of ischemic events and those who are not. The optimal platelet reactivity test has yet to be determined, and no large, randomized trial to date has successfully demonstrated the effectiveness of tailoring antiplatelet medications according to the platelet reactivity of individual patients for improved clinical outcomes. Therefore, the present role for platelet reactivity monitoring is selective and limited. Copyright Remedica Medical Education and Publishing.",
author = "Oestreich, {Julie H.} and Dobesh, {Paul P}",
year = "2011",
month = "9",
day = "6",
language = "English (US)",
volume = "10",
pages = "55--62",
journal = "Acute Coronary Syndromes",
issn = "1369-5312",
publisher = "Remedica Medical Education and Publishing Ltd",
number = "2",

}

TY - JOUR

T1 - Platelet reactivity testing

T2 - An objective analysis of current capability

AU - Oestreich, Julie H.

AU - Dobesh, Paul P

PY - 2011/9/6

Y1 - 2011/9/6

N2 - High on-treatment platelet reactivity is associated with adverse cardiovascular events following percutaneous coronary intervention. In analyses based on areas under receiver operating characteristic curves, platelet reactivity tests have poor-to-fair ability to discriminate between patients who are at risk of ischemic events and those who are not. The optimal platelet reactivity test has yet to be determined, and no large, randomized trial to date has successfully demonstrated the effectiveness of tailoring antiplatelet medications according to the platelet reactivity of individual patients for improved clinical outcomes. Therefore, the present role for platelet reactivity monitoring is selective and limited. Copyright Remedica Medical Education and Publishing.

AB - High on-treatment platelet reactivity is associated with adverse cardiovascular events following percutaneous coronary intervention. In analyses based on areas under receiver operating characteristic curves, platelet reactivity tests have poor-to-fair ability to discriminate between patients who are at risk of ischemic events and those who are not. The optimal platelet reactivity test has yet to be determined, and no large, randomized trial to date has successfully demonstrated the effectiveness of tailoring antiplatelet medications according to the platelet reactivity of individual patients for improved clinical outcomes. Therefore, the present role for platelet reactivity monitoring is selective and limited. Copyright Remedica Medical Education and Publishing.

UR - http://www.scopus.com/inward/record.url?scp=80052274556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052274556&partnerID=8YFLogxK

M3 - Review article

VL - 10

SP - 55

EP - 62

JO - Acute Coronary Syndromes

JF - Acute Coronary Syndromes

SN - 1369-5312

IS - 2

ER -